HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao maintains a Buy rating on Theravance Biopharma (NASDAQ:TBPH) but lowers the price target from $20 to $15.
August 06, 2024 | 7:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. maintains a Buy rating on Theravance Biopharma but lowers the price target from $20 to $15.
The Buy rating suggests continued confidence in the stock, but the lowered price target indicates tempered expectations for future performance. This mixed signal may result in neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100